Clinical Trials Browser

Phase 1/2 × carfilzomib × 1 year × Clear all

NCT07463807 2026-03-19

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07479979 2026-03-18

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT05434689 2026-03-05

COMMANDER

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT02937571 2025-11-20

High Dose Carfilzomib for Newly Diagnosed Myeloma

Phase 1/2 Completed

29 enrolled 10 charts

Multiple Myeloma

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

Multiple Myeloma, Recurrence